Almost all neuroblastoma tumors express excess levels of Cyclin D1 (CCND1) compared to normal tissues and other tumor types. Only a small percentage of these neuroblastoma tumors have high-level amplification of the Cyclin D1 gene. The other neuroblastoma tumors have equally high Cyclin D1 expression without amplification. Silencing of Cyclin D1 expression was previously found to trigger differentiation of neuroblastoma cells. Overexpression of Cyclin D1 is therefore one of the most frequent mechanisms with a postulated function in neuroblastoma pathogenesis. The cause for the Cyclin D1 overexpression is unknown. Here we show that Cyclin D1 overexpression results from transcriptional upregulation. To identify upstream regulators, we searched in mRNA profiles of neuroblastoma tumor series for transcription factors with expression patterns correlating to Cyclin D1. GATA3 most consistently correlated to Cyclin D1 in four independent data sets. We identified a highly conserved GATA3 binding site 27 bp upstream of the Cyclin D1 transcriptional start. Chromatin immune precipitation confirmed binding of GATA3 to the Cyclin D1 promoter. Overexpression of GATA3 induced Cyclin D1 promoter activity, which decreased after site-directed mutagenesis of the GATA3 binding site in the Cyclin D1 promoter. Silencing of GATA3 resulted in reduced Cyclin D1 promoter activity and reduced Cyclin D1 mRNA and protein levels. Moreover, GATA3 silencing caused differentiation that was similar to that caused by Cyclin D1 inhibition. These finding implicate GATA3 in Cyclin D1 overexpression in neuroblastoma.
Introduction
The cell cycle is a tightly controlled process that is deregulated in all cancer cells (Hanahan and Weinberg, 2000) . Several checkpoints normally prevent premature cell-cycle progression and cell division. The crucial G1 entry point is controlled by the D-type Cyclins that can activate CDK4/6 that in turn phosphorylate the pRb protein. This results in a release of the E2F transcription factor that causes transcriptional upregulation of numerous genes involved in further progression of the cell cycle (Sherr, 1996) .
Neuroblastomas are embryonal tumors that originate from precursor cells of the sympathetic nervous system. This tumor has a very poor prognosis and despite the low frequency it is the second cause of cancer-related deaths in children (van Noesel and Versteeg, 2004; Maris et al., 2007) . The G1 checkpoint is deregulated in neuroblastoma in various ways. Sporadic CDKN2A (p16) mutations and CDK4 amplifications have been reported but most striking is the extensive overexpression of Cyclin D1 (Van Roy et al., 1995; Molenaar et al., 2003; Caren et al., 2008) . We have previously shown a very high expression on mRNA and protein level compared to normal tissue and even compared to other tumors with known high expression levels of Cyclin D1. Functional evaluation of Cyclin D1 in neuroblastoma showed a crucial function in maintaining the undifferentiated phenotype of the neuroblasts in vitro and in vivo (Molenaar et al., 2008) . A genomic cause for the extensive Cyclin D1 overexpression could be identified in a minority of cases. We have previously reported high-level genomic amplification of the Cyclin D1 gene in 5 out of 202 neuroblastoma tumors and cell lines. Others also reported recurrent high-level genomic amplifications of the 11q13 region encompassing the Cyclin D1 gene (Molenaar et al., 2003; Michels et al., 2007) . These clonal events clearly pointed to a crucial function for Cyclin D1 in neuroblastoma tumor genesis, but could not explain the overexpression of Cyclin D1 in about 75% of the remaining neuroblastomas, that showed Cyclin D1 expression levels reaching equal or even higher levels compared to tumors with genomic amplification.
Identification of the mechanism that drives Cyclin D1 overexpression in neuroblastomas is therefore an important question. In this paper, we identify by in silico analysis the GATA3 transcription factor as a candidate regulator of Cyclin D1. We show that GATA3 binds to the Cyclin D1 promoter and that silencing of GATA3 reduced promoter activity, resulting in decreased Cyclin D1 mRNA and protein levels, as well as in differentiation of neuroblastoma cells.
Results
Identification of GATA3 as possible regulator of Cyclin D1 using mRNA profiling Cyclin D1 is extremely highly expressed in over 75% of the neuroblastoma tumors, whereas CCND1 genetic aberrations are much more infrequent. To search for the mechanism behind Cyclin D1 overexpression, we first analyzed whether upregulation was transcriptionally mediated. We cloned a 1882-bp Cyclin D1 promoter fragment encompassing the region 1696 bp upstream to 186 downstream of the transcription start site of Cyclin D1 (numbered according to NCBI Reference Sequence NM_053056.2) in a pGL3 reporter vector. This construct was transfected together with a Renilla luciferase control construct into several different neuroblastoma cell lines that had a wide range of Cyclin D1 expression levels as based on Affymetrix (Santa Clara, CA, USA) expression data. The cells were harvested during exponential growth, and the relative Cyclin D1 promoter activity determined by a dual luciferase assay. The relative Cyclin D1 promoter activity showed a very clear correlation to the endogenous Cyclin D1 mRNA expression levels ( Figure 1a ). This suggested that the high expression of Cyclin D1 in neuroblastoma results from transcriptional upregulation.
To identify transcription factors that regulate Cyclin D1 expression in neuroblastoma, we used Affymetrix mRNA expression data. We hypothesized that the mRNA expression level of a transcription factor that causes the overexpression of Cyclin D1 might be related to the level of Cyclin D1 mRNA expression. We have built the R2 bioinformatic analysis program (http://hgserver1.amc.nl), which allows easy identification of correlations in gene expression in tumor series analyzed by expression arrays. The R2 application contains Affymetrix mRNA expression data of four different neuroblastoma tumor sets in the public domain. We searched these four data sets for genes in the Gene-Ontology category 'transcription factors' (GO 3700). Of the 945 genes in this category, GATA3 showed the highest correlation to the Cyclin D1 expression levels (Table 1 ). This raised the possibility that GATA3 is involved in transcriptional regulation of Cyclin D1. The correlation in the series of 110 neuroblastic tumors profiled in our lab is shown in detail in Figure 1b . There is a strong correlation between the GATA3 and Cyclin D1 mRNA expression profiles, with one striking exception (sample with circle). This outlier has high Cyclin D1 expression, but only low GATA3 expression. The sample appeared to have high-level genomic amplification of the Cyclin D1 gene. This suggests that high Cyclin D1 expression in neuroblastoma is either caused by genomic amplification of Cyclin D1, or related to high GATA3 expression. Samples ordered by CCND1 Figure 1 Affymetrix microarray analysis suggests Cyclin D1 transcriptional upregulation by GATA3. (a) Cyclin D1 mRNA expression and Cyclin D1 promoter activity in neuroblastoma cell lines: mRNA was isolated from neuroblastoma cell lines using Trizol (Invitrogen, Breda, Netherlands). mRNA was labeled and hybridized on Affymetrix HG-U133 Plus 2.0 arrays. Expression was normalized using the MAS5.0 algorithm. For Cyclin D1 promoter activity, a Cyclin D1 promoter fragment encompassing nucleotides À1696 to 186 according to NM_053056.2 was taken from a pA3 vector and cloned in the pGL3 Firefly luciferase reporter plasmid (Albanese et al., 1995) . Neuroblastoma cell lines were co-transfected with the Cyclin D1 promoter reporter and a Renilla luciferase expression vector as an internal transfection control. Luciferase activity was measured using the Promega (Madison, WI, USA) Dual-Luciferase Reporter Assay System and Cyclin D1 promoter activity was defined as firefly luciferase activity/Renilla luciferase activity. (b) YY plot of Cyclin D1 and GATA3 Affymetrix expression in 110 neuroblastic tumors: Material collection and RNA isolation procedures were described previously (Molenaar et al., 2008) . MAS5.0 corrected data are shown. The tumor sample indicated by the circle contains a strong genomic amplification of the 11q13 region containing Cyclin D1. 2log values of Cyclin D1 and GATA3 expression are indicated by red and blue dots, respectively. For each tumor sample several characteristics are given as tracks (color coded boxes). Survival (red, death; light green, survival 0-5 years; dark green, survival 45 years); INSS (red, stage 3 or 4; green, stage 1 or 2; orange, stage 4S); histology (red, neuroblastoma; dark green, ganglioneuroblastoma; light green, ganglioneuroma); MYCN (green, nonamplified; red, amplification410 copies). A full colour version of this figure is available at the Oncogene journal online.
GATA3 binding to a newly identified GATA3 binding site in the Cyclin D1 promoter
To validate a functional relation between the GATA3 transcription factor and Cyclin D1, we generated three different siRNAs targeting various 21 bp sequences in the coding region of GATA3. The best siRNA showed 60% silencing of GATA3 as analyzed by Q-PCR, and this siRNA was selected for further experiments (data not shown). To analyze whether GATA3 silencing results in a decrease in Cyclin D1 promoter activity, we used the Cyclin D1 promoter construct as described above. The IMR-32 and SK-N-BE neuroblastoma cell lines were co-transfected with the Cyclin D1 promoter reporter construct and a constitutively active Renilla luciferase expression vector as internal transfection control. In addition, these cells were transfected with GATA3 siRNA or a GFP siRNA control. Figure 2a shows that GATA3 silencing results in a decreased Cyclin D1 promoter activity in both neuroblastoma cell lines. Inversely the overexpression of GATA3 in neuroblastoma cell lines with low GATA3 levels should lead to an induction of Cyclin D1 promoter activity. Therefore, we selected a neuroblastoma cell line with undetectable GATA3 (SHEP-21-N) and a cell line with low GATA3 (SK-N-AS) expression based on Affymetrix mRNA profiling data. These cell lines were cotransfected with a GATA3 overexpression construct (Usary et al., 2004) and the Cyclin D1 promoter reporter. The Renilla luciferase expression vector was used as internal transfection control. Both cell lines show a strong induction of Cyclin D1 promoter activity (2.6-and 2.7-fold, respectively) on GATA3 overexpression ( Figure 2b ).
To identify whether the reduction in Cyclin D1 promoter activity resulted from a direct or indirect regulation by GATA3, we searched for candidate GATA3 binding sites within the Cyclin D1 promoter. We performed a high-stringency search for GATA3 binding sites conserved among (different) species using three GATA3 position weight matrices provided by the Transfac database. This search yielded one highly conserved match, 27-19 bp upstream of the Cyclin D1 transcriptional start site (Figure 2c ). To test whether GATA3 binds this cis element, we performed a chromatin immunoprecipitation (ChIP) assay. Chromatin isolated from IMR-32 cells was used for a pull-down experiment with a GATA3 antibody, as well as a FLAG antibody as a negative control. Following DNA isolation, Q-PCR was performed using primers surrounding the GATA3 binding site in the Cyclin D1 promoter (PP1), or primers further upstream in the promoter (PP2). The results showed a strong enrichment for the DNA fragment containing the postulated GATA3 binding site, confirming binding of GATA3 to the Cyclin D1 promoter in neuroblastoma tumor cells (Figure 2d ). To show loss of function of this GATA3 binding site, we performed site-directed mutagenesis on two positions at the core GATA3 binding site (Figure 2c ) in the full-length Cyclin D1 promoter construct. After overexpression of GATA3, the mutated Cyclin D1 promoter construct shows a clear reduction in activity compared to the wild-type construct in both cell lines. The reduction in promoter activity is 40% (SHEP-21-N) and 35% (SK-N-AS) if we take the activity level without GATA3 overexpression as the basal level (Figure 2b ). The partially reduced activity in the mutated Cyclin D1 promoter reporter might indicate that there are other less conserved GATA3 binding sites in the Cyclin D1 promoter that also influence the activity. Together these results suggest a functional role of GATA3 as transcription factor in activation of the Cyclin D1 promoter.
GATA3 silencing in neuroblastoma cell lines causes Cyclin D1 downregulation Our results predicted that knockdown of GATA3 would result in reduced levels of Cyclin D1. Therefore, we transfected the most potent GATA3 siRNA in the neuroblastoma cell line IMR-32. Control samples were Correlations were calculated between the Affymetrix expression of Cyclin D1 and all transcription factors defined in the gene ontology database.
The significance of finding a certain correlation (P-value) is calculated by the following formula: t ¼ r/O((1Àr 2 )/(nÀ2)), where r corresponds to the correlation value and n denotes the number of samples. The text between brackets indicates the number of tumors in the data set and the type of Affymetrix microarray. The Versteeg data set has been previously published (Molenaar et al., 2008) . The other data sets were taken from the NCBI GEO database (gse3960, gse3446 and gse12460).
transfected with a GFP siRNA. RNA was harvested 48 h after transfection, and GATA3 and Cyclin D1 levels determined using Q-PCR analysis. Figure 3a shows a 60% knock down of GATA3 followed by a 40% reduction of Cyclin D1 mRNA. Also western blot analysis showed a good knockdown of GATA3 followed by a decrease in Cyclin D1 protein (Figure 3b ). Phenotypic analysis of the IMR-32 cells using light microscopy clearly showed reduced cell proliferation as well as the formation of neurite and SK-N-BE: both cell lines were co-transfected with the full-length Cyclin D1 promoter reporter construct and a constitutive active Renilla luciferase expression vector as an internal transfection control as described above. In addition these cells were transfected with GATA3 siRNA or a GFP siRNA control (see Supplementary Table 1 for sequences). Luciferase activity was measured and Cyclin D1 promoter activity defined as described above. The relative Cyclin D1 promoter activity in the control sample was set to 100. (b) Activity of the Cyclin D1 promoter and Cyclin D1 promoter with mutated GATA3 binding site after GATA3 overexpression in cell lines with low endogenous GATA3 expression. The Cyclin D1 promoter construct was mutated in the core GATA3 binding site at two positions using the Quikchange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). Primers are given in the supplementary data. SHEP-21-N and SK-N-AS cell lines were co-transfected with the full-length Cyclin D1 promoter reporter construct or a fulllength Cyclin D1 promoter construct with mutated GATA3 binding site together with a constitutively active Renilla luciferase expression vector as an internal transfection control. In addition, these cells were transfected with a pBabe plasmid containing the GATA3 coding sequence or an empty vector (Usary et al., 2004) . After 48 h the Luciferase activities were measured as described above. The relative Cyclin D1 promoter activity of the cells transfected with the nonmutated construct without GATA3 overexpression was set to 100. Assays were performed in triplicate and the error bars give the standard deviation. (c) Overview of the Cyclin D1 promoter region with the location of the GATA3 binding site, the ChIP primer pairs and the full-length promoter construct. The CCND1 promoter sequence was extracted from Human Genome assembly version 18 (Hg18) as provided by the UCSC Genome Browser. The conserved GATA3 binding site was detected using three available matrices for GATA3 from Transfac 11.1 (V$GATA3_01, V$GATA3_02 and V$GATA3_03). These were searched against the CCND1 promoter region using the Storm program from the CREAD package. A P-value of 0.0001 was used as a match threshold against whole-genome intergenic sequence hit-tables constructed for each genome searched. This search of the CCND1 promoter region was first carried out in the Hg18 sequence and subsequently in the orthologous regions of 19 other genomes. Requiring that a site be conserved in at least seven species, a single GATA3 binding site was identified that most closely matched the V$GATA3_03 matrix. (d) ChIP analysis using GATA3 antibody and Cyclin D1 promoter primers. A modified protocol of the Upstate ChIP kit was used (Upstate, Charlottesville, VA, USA). ChIP was performed with either 1 mg of GATA3 antibody or 1 mg of anti-FLAG-antibody (as a negative control) and protein-A agarose. For each ChIP sample, the precipitated chromatin was finally dissolved in 30 ml water. These samples were amplified using a ligation-mediated PCR. DNA (50 ng) of all ChIP samples and of the input DNA was analyzed with SYBR Green based quantitative PCR. Primer pairs were checked for specificity by melting curve analysis and gel electrophoresis. Primer pair efficiencies were determined by the slope of PCR curves, and were comparable at different template concentrations. Each ChIP and following PCR was performed in fourfold. A complete list of all the primers and antibodies used for ChIP analysis is listed in the Supplementary Table 1. The Ct was calculated using iCycler (Bio-Rad, Veenendaal, Netherlands) software and the figure shows the DCt, which is the Ct of the input sampleÀthe Ct of the calculated sample. Error bars show the standard error.
extensions (Figure 3c ). To exclude off-target effects, we used a second RNA interference technique and another target sequence. Lentiviral transduction was used to infect IMR-32 and SK-N-BE cells with a GATA3 shRNA expressing vector. Again, western blot analysis showed that GATA3 was efficiently silenced and that Cyclin D1 expression also decreased (Figure 3d ), confirming the findings in the transient GATA3 siRNA experiments.
Discussion
Our results identify GATA3 as a gene involved in transcriptional regulation of Cyclin D1. Identification of transcription factor target genes by comparative genomics based on expression profiling has been shown before (Vallania et al., 2009) . We now used the same method in reverse. Identification of correlating transcription factors made it possible to identify a likely upstream regulator of an important oncogene in neuroblastic tumors. The exception formed by the tumor with strong genomic Cyclin D1 amplification in the GATA3/Cyclin D1 correlation analysis is striking (Figure 1b) . One could consider including this outlier approach to predict upstream regulators even more accurate. The transcriptional regulation of Cyclin D1 suggests oncogenic potential for the GATA3 transcription factor. GATA3 has been shown to be crucial in neural crest cell differentiation by transcriptional activation of the TH Table 1 ) (Molenaar et al., 2008) . Cells were harvested after 48 h. Trizol RNA isolation and cDNA production were performed using standard procedures. Q-PCR was carried out on cDNA with primers described in supplementary information using the real-time iCycler PCR platform (Bio-Rad) in combination with the intercalating fluorescent dye SYBR Green I. Expression was normalized to a control (PSMB1) gene and calculated using iCycler software. The expression of GATA3 and Cyclin D1 in the GFP siRNA control samples was set to 1. Error bars show the standard error. (b) Western blot of IMR32 after GATA3 knockdown. Cells used for the experiments described in Figure 3a were harvested for protein isolation using Laemmli extraction buffer. Western blot analysis was performed as described previously (Molenaar et al., 2003) . Antibody descriptions can be found in the supplementary data. (c) Light microscopy pictures of cells after GATA3 or GFP control siRNA treatment after 72 h. (d) Western blot analysis of GATA3 and Cyclin D1 after lentiviral GATA3 shRNA knockdown in IMR-32 and SK-N-BE. Lentivirus expressing shRNA constructs targeting GATA3 or a control nontargeting shRNA were produced in the HEK-293T packaging cell line following standard procedures. Virus was concentrated by ultracentrifugation at 32 000 r.p.m. for 1 h, and virus titers determined by a p24 ELISA assay. A MOI (multiplicity of infection) of 1 was used for the experiments. At 24 h after virus addition, medium was refreshed, and protein isolated after an additional 72 h. Western blot analysis was as described above.
and DBH noradrenaline synthesis genes, but also by controlling cell survival and early sympathetic neuronal development (Lim et al., 2000; Tsarovina et al., 2004; Hong et al., 2006 Hong et al., , 2008 . The direct transcriptional control of Cyclin D1 could be in line with the function of GATA3 in development of a fast dividing population of neural crest cells. Moreover, we have previously shown that Cyclin D1 is crucial in maintaining the undifferentiated phenotype of neuroblastoma cells (Molenaar et al., 2008) . This raises the possibility that the function of GATA3 in maintaining sympathetic neuronal cells in a certain differentiation state could be mediated through its activation of Cyclin D1. Sustained activity of GATA3 in neuroblastoma cells could then be considered oncogenic, because it maintains the high Cyclin D1 expression with a consequent increased proliferation rate and block in further differentiation.
We show an overexpression of GATA3 in neuroblastoma tumors but also in breast cancer GATA3 is known to be highly expressed in a subset of tumors (estrogen receptor-positive cells) (Hoch et al., 1999; Kouros-Mehr et al., 2006 . Within the group of estrogen receptor-positive cells the GATA3 transcription factor is crucial for cell-cycle progression (Eeckhoute et al., 2007; Wilson and Giguere, 2008) possibly through the inhibition of CDKN2C (Pei et al., 2009) . It might be also of interest to study the activity of GATA3 on the Cyclin D1 promoter in breast cancer cells.
The high GATA3 expression suggests clonal events but we could not detect any amplifications or gain of GATA3 by Southern blot analysis of 105 primary neuroblastoma tumor samples (results not shown). Alternatively, the overexpression of GATA3 could result by other upstream events that maintain a high GATA3 expression. PHOX2B is known to regulate GATA3 and PHOX2B activating mutations have been identified in neuroblastoma tumors (van Limpt et al., 2004; Tsarovina et al., 2004) . In addition, GATA3 regulating miRNAs could be downregulated in neuroblastoma.
We have shown direct involvement of the GATA3 transcription factor in activation of the driving oncogene Cyclin D1 that is overexpressed in 75% of the neuroblastomas, implicating GATA3 in the pathogenesis of neuroblastoma.
